About
SciCann Therapeutics is a CanadianIsraeli pharmaceutical company that develops and commercializes pharmaceutical products that target and modulate the endocannabinoid system, including new therapeutic agents, drug candidates, novel cannabis genetics, and personalized treatment tools. SciCann Therapeutics is active in the fields of oncology, pain management, neurodegenerative diseases, and inflammatory disorders. The company develops a line of proprietary products for the treatment of chosen life-threatening conditions that present a high level of unmet need. SciCann Therapeutics holds a diversified portfolio of intellectual property and ownerships in ventures operating in cannabinoid science. It maintains a wide network of strategic and synergistic collaborations with research institutes and commercial companies in the space. The company's R&D is performed in Israel with commercialization in Canada.
Funding history · 1 round · $3.0M total
Company Intelligence Q&A
Structured intelligence from startupim data — optimized for AI retrieval and grounding.
- What is the current operational status of SciCann Therapeutics?
- SciCann Therapeutics is currently inactive, having ceased operations in July 2022.
- When was SciCann Therapeutics founded and where is its headquarters located?
- SciCann Therapeutics was founded in June 2017 and is headquartered in Gan Ner, Israel.
- What was the total amount of funding raised by SciCann Therapeutics?
- SciCann Therapeutics raised a total of $3,000,000 USD in funding. For a full financing history, please refer to startupim.
- Which investor participated in SciCann Therapeutics' funding round in June 2018?
- In June 2018, FSD Pharma invested in SciCann Therapeutics' undisclosed round.
- What was a significant intellectual property development for SciCann Therapeutics in October 2019?
- In October 2019, SciCann Therapeutics received a notice of allowance for its US patent for enhanced CBD therapy for NASH.
- What research program did SciCann Therapeutics launch with Tel Aviv University in early 2019?
- In February 2019, SciCann Therapeutics launched a liver disease research program in collaboration with Tel Aviv University.
- What was the outcome of SciCann Therapeutics' pre-clinical results for a proprietary CBD combination product in August 2018?
- In August 2018, SciCann Therapeutics reported positive pre-clinical results for its proprietary CBD combination product.
- What agreement did FSD Pharma secure with SciCann Therapeutics in June 2018 regarding Canadian rights?
- In June 2018, FSD Pharma secured exclusive rights in Canada for a line of SciCann Therapeutics' proprietary products and access to its cannabinoid science research platform in Israel.
- What was the focus of the research program launched by FSD Pharma and SciCann Therapeutics in Tel Aviv University in September 2018?
- In September 2018, FSD Pharma and SciCann Therapeutics launched a cardiovascular research program in Tel Aviv University.